Clinical Trial Update: ARIXTRA Local Study For Registration In China. [Phase 3]

View source ↗

Summary

Phase 3 trial update for ARIXTRA evaluating prophylaxis of venous thromboembolism in knee and hip replacement patients; the study in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• ARIXTRA (fondaparinux sodium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Thromboembolism, Knee Replacement | Phase 3 | Status: COMPLETED